Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Barinthus Biotherapeutics's EV-to-OCF or its related term are showing as below:
STU:2AB'
s EV-to-OCF Range Over the Past 10 Years
Min: -28.43 Med: 1.05 Max: 9.49
Current: 0.94
During the past 7 years, the highest EV-to-OCF of Barinthus Biotherapeutics was 9.49. The lowest was -28.43. And the median was 1.05.
STU:2AB's EV-to-OCF is ranked worse than 77.38% of 1410
companies
in the Biotechnology industry
Industry Median: -3.52
vs STU:2AB: 0.94
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Barinthus Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Barinthus Biotherapeutics's share price for today is €0.494.
Barinthus Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.885.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Barinthus Biotherapeutics EV-to-OCF Related Terms
Barinthus Biotherapeutics EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Barinthus Biotherapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's EV-to-OCF falls into.
Barinthus Biotherapeutics's current Enterprise Value is €-22.13 Mil.
Barinthus Biotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-22.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a EV-to-OCF of 0.98 as of Aug. 15, 2026. This is near median its historical median of 1.05. According to the industry distribution chart, Barinthus Biotherapeutics ranks #1091 out of 1410 companies in the Biotechnology industry, placing it in the top 77.4%.
Is Barinthus Biotherapeutics' EV-to-OCF too high?
Barinthus Biotherapeutics' current EV-to-OCF of 0.98 is near median its 10-year median of 1.05. Based on the distribution chart, Barinthus Biotherapeutics ranks #1091 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' EV-to-OCF compare to CRVO and ALGS?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #1091 out of 1410 companies for EV-to-OCF. This places Barinthus Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Barinthus Biotherapeutics's current EV-to-OCF is 0.98, which is near median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current EV-to-OCF of 0.98. The stock's GF Value™ is €0.94, compared to a current price of €0.49 — trading 47.4% below its estimated fair value. The current EV-to-OCF is 0.98, which is near median its 10-year median of 1.05. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current EV-to-OCF is 0.98 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.49 is trading 47.4% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
EV-to-OCF: 0.98 (near median its 10-year median of 1.05)
GF Value™: €0.94 vs. price of €0.49 (47.4% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
